الثلاثاء 9 جمادى الأولى 1448هـ
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
تحقق من أن الموقع يستخدم بروتوكول HTTPS
مسجل لدى هيئة الحكومة الرقمية برقم :
| عنوان الدراسة | داعم الدراسة | حالة الدراسة | دواء الدراسة | مرحلة الدراسة | رقم بروتوكول الدراسة | موقع الدراسة |
|---|---|---|---|---|---|---|
| A Phase 4, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Effectiveness and Safety of Tirzepatide Once Weekly in Adult Participants with Type 2 Diabetes during Ramadan (T-RAM) | Boehringer Ingelheim | Ongoing | BI 690517 Empagliflozin | 4 | 1378-0020 | King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz University Hospital (Jeddah) |
| INTERnational STudy Evaluating Lupus Outcomes after Anifrolumab Real-World Use (INTERSTELLAR): Multi-National, Observational, Prospective, Post-Launch, Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice | AstraZeneca | Ongoing | Anifrolumab | 4 | TMP-0010230 | Aseer Central Hospital (Abha), International Medical Center (Jeddah) |
| Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects with Severe or Moderately Severe Hemophilia B with Detectable Pretreatment AAV5 Neutralizing Antibodies | CSL Behring LLC | Ongoing | HEMGENIX (etranacogene dezaparvovec) | 3b | CSL222_3005 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Long-term pain and adherence observational study for Endometriosis treatment | Abbott | Ongoing | Duphaston | 4 | DYDR-522-0318 | Dr.Arab Clinic |
| Real world Assessment of Dyslipidemia patients on Inclisiran effiCacy And toLerability: The RADICAL Study | Novartis | Ongoing | LEQVIO | 4 | CKJX839A1S | Dallah Hospital (Riyadh),International Medical Center (Jeddah), Armed Force Hospital (Tabuk),My Clinic (Jeddah), Mouwasat Hospital (Dammam) |
| Effect of celecoxib on postoperative narcotic use and disease severity in patients with aspirin-exacerbated respiratory disease and chronic rhinosinusitis: a randomized controlled trial | King Khalid University Hospital | Ongoing | Celecoxib | 4 | 114809 | King Khalid University Hospital (Riyadh), King Abdulaziz University Hospital (Riyadh) |
| EASi-HF - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) >40% | Boehringer Ingelheim | Ongoing | BI 690517 , empagliflozin | 3 | 1378-0020 | King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh),King Abdulaziz Medical City NG (Riyadh), King Abdulaziz University Hospital (Jeddah) |
| Effect of Probiotics “Psychobiotics” on Depression in Adults with Obesity and Metabolic Syndrome in Riyadh City | King Khalid University Hospital | Ongoing | Winclove’s Ecologic® Barrier probiotics | 3 | E-23-7867 | King Khalid University Hospital (Riyadh) |
| BalanceD-HF: A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function | AstraZeneca | Ongoing | balcinrenone/dapagliflozin | 3 | D6402C00012 | King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical NG (City Riyadh),King Abdulaziz Medical City NG (Jeddah),King Fahad Medical City (Riyadh) ,King Khalid University Hospital (Riyadh) |
| A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) | Janssen Research & Development | Rejected | Nipocalimab | 3 | 80202135EBF3001 | King Faisal Specialist Hospital and Research Center (Riyadh), King Saud Medical City (Riyadh), King Fahad University Hospital (Al-Khobar) |
تاريخ آخر تحديث: 06/10/2026 بتمام الساعة 08:14 صباحا بتوقيت المملكة العربية السعودية
لم يتم تقديم أي تقييمات لهذه الصفحة بعد.
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.